Thomas F. Dejgaard, Denmark

Steno Diabetes Center Copenhagen T1D Biology

Moderator of 1 Session

E-POSTER DISCUSSION
Session Type
E-POSTER DISCUSSION
Channel
Station 5 (E-Poster Area)
Date
20.02.2020, Thursday
Session Time
10:05 - 10:25

Presenter of 1 Presentation

GLP-1 and DPP-IV in type 1 diabetes

Session Type
PARALLEL SESSION
Date
20.02.2020, Thursday
Session Time
16:40 - 18:00
Channel
Rome
Lecture Time
17:20 - 17:40

Abstract

Background and Aims

Insulin treatment of persons with type 1 diabetes has shortcomings and many patients do not achieve glycaemic and metabolic targets. Consequently, the focus is on novel non-insulin therapeutic approaches that reduce hyperglycaemia and improve metabolic variables without increasing the risk of hypoglycaemia, weight gain or other adverse events. Several therapies given in conjunction with insulin have been investigated in clinical trials, including dipeptidyl peptidase-IV (DPP-IV) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs have pleiotropic effects on glucose metabolism and different actions complementary to those of insulin.

Overall, DPP-IV inhibitors added to insulin treatment in persons with type 1 diabetes have shown a modest, but non-clinically relevant reduction in HbA1c with no raised risk of hypoglycaemia and no effect on body weight have been reported. More promising, a significant reduction in body weight and daily insulin dose combined with reductions in HbA1c have been reported with the use of GLP-1 receptor agonists in type 1 diabetes.

Both DPP-IV inhibitors and GLP-1 receptor agonists seem to be well tolerated, however symptomatic hypoglycaemia and hyperglycaemia with ketosis when adding a GLP-1 receptor agonist to insulin in type 1 diabetes have been reported.

Currently, there are no DPP-IV inhibitors, nor GLP-1 receptor agonists approved for the treatment of type 1 diabetes – should there be?

Hide